Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)
- PMID: 28335948
- DOI: 10.1016/j.ophtha.2016.08.034
Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)
Comment in
-
Reply.Ophthalmology. 2017 Apr;124(4):e38-e39. doi: 10.1016/j.ophtha.2016.08.032. Ophthalmology. 2017. PMID: 28335949 No abstract available.
Comment on
-
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022. Epub 2016 Feb 27. Ophthalmology. 2016. PMID: 26935357 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources